You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Twitter Demographics
Mendeley readers
Attention Score in Context
| Title |
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
|
|---|---|
| Published in |
Cancer Research, June 2023
|
| DOI | 10.1158/0008-5472.can-23-0593 |
| Pubmed ID | |
| Authors |
Arian Lundberg, Meng Zhang, Rahul Aggarwal, Haolong Li, Li Zhang, Adam Foye, Martin Sjöström, Jonathan Chou, Kevin Chang, Thaidy Moreno-Rodriguez, Raunak Shrestha, Avi Baskin, Xiaolin Zhu, Alana S. Weinstein, Noah Younger, Joshi J. Alumkal, Tomasz M. Beer, Kim N. Chi, Christopher P. Evans, Martin Gleave, Primo N. Lara, Rob E. Reiter, Matthew B. Rettig, Owen N. Witte, Alexander W. Wyatt, Felix Y. Feng, Eric J. Small, David A. Quigley |
| Abstract |
Systemic targeted therapy in prostate cancer is primarily focused on ablating androgen signaling. Androgen deprivation therapy and second-generation androgen receptor (AR)-targeted therapy selectively favor the development of treatment-resistant subtypes of metastatic castration-resistant prostate cancer (mCRPC), defined by AR and neuroendocrine (NE) markers. Molecular drivers of double-negative (AR-/NE-) mCRPC are poorly defined. In this study, we comprehensively characterized treatment-emergent mCRPC by integrating matched RNA sequencing, whole-genome sequencing, and whole-genome bisulfite sequencing from 210 tumors. AR-/NE- tumors were clinically and molecularly distinct from other mCRPC subtypes, with the shortest survival, amplification of the chromatin remodeler CHD7, and PTEN loss. Methylation changes in CHD7 candidate enhancers were linked to elevated CHD7 expression in AR-/NE+ tumors. Genome-wide methylation analysis nominated KLF5 as a driver of the AR-/NE- phenotype, and KLF5 activity was linked to RB1 loss. These observations reveal the aggressiveness of AR-/NE- mCRPC and could facilitate the identification of therapeutic targets in this highly aggressive disease. |
Twitter Demographics
The data shown below were collected from the profiles of 28 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 12 | 43% |
| Japan | 1 | 4% |
| Netherlands | 1 | 4% |
| Canada | 1 | 4% |
| Switzerland | 1 | 4% |
| China | 1 | 4% |
| United Kingdom | 1 | 4% |
| Unknown | 10 | 36% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 16 | 57% |
| Members of the public | 9 | 32% |
| Practitioners (doctors, other healthcare professionals) | 2 | 7% |
| Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 3 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Unspecified | 2 | 67% |
| Researcher | 1 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Unspecified | 2 | 67% |
| Medicine and Dentistry | 1 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 September 2023.
All research outputs
#1,822,799
of 24,490,209 outputs
Outputs from Cancer Research
#1,262
of 18,816 outputs
Outputs of similar age
#33,393
of 362,101 outputs
Outputs of similar age from Cancer Research
#14
of 90 outputs
Altmetric has tracked 24,490,209 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 18,816 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 362,101 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 90 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.